Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Specialty Sites
    • Equity, Diversity and Inclusion
    • Innovations in Care Delivery
    • Without Borders
  • Collections
    • Topics A-Z
    • Residents & Fellows
    • Infographics
    • Patient Pages
    • Null Hypothesis
    • Translations
  • Podcast
  • CME
    • Article CME
    • Podcast CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Specialty Sites
    • Equity, Diversity and Inclusion
    • Innovations in Care Delivery
    • Without Borders
  • Collections
    • Topics A-Z
    • Residents & Fellows
    • Infographics
    • Patient Pages
    • Null Hypothesis
    • Translations
  • Podcast
  • CME
    • Article CME
    • Podcast CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Residents & Fellows

User menu

  • Subscribe
  • My alerts
  • Log in

Search

  • Advanced search
Neurology
Home
The most widely read and highly cited peer-reviewed neurology journal
  • Subscribe
  • My alerts
  • Log in
Site Logo
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Residents & Fellows

Share

January 30, 2018; 90 (5) Patient Page

Black patients missing out on stroke treatmentAbout stroke and its treatments

Altaf Saadi
First published January 29, 2018, DOI: https://doi.org/10.1212/WNL.0000000000004904
Altaf Saadi
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Full PDF
Citation
Black patients missing out on stroke treatmentAbout stroke and its treatments
Altaf Saadi
Neurology Jan 2018, 90 (5) e444-e446; DOI: 10.1212/WNL.0000000000004904

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
154

Share

  • Article
  • Info & Disclosures
Loading

Why was the study done?

IV tissue plasminogen activator (tPA) is a clot-busting medication that can be used to treat ischemic strokes. Ischemic strokes are caused by clots that block blood flow to the brain. tPA is infused into a patient's arm through an IV. It can dissolve a clot and restore blood flow to the part of the brain that had been cut off. The tricky part is that for the tPA to work, it must be given within 4.5 hours of stroke onset. When patients are given tPA, they have higher chances of getting better from their stroke.

But more than 20 years after the approval of tPA, and despite efforts to make people aware of its use, only about 3%–7% of stroke patients actually receive the drug in the United States. The rates of tPA use among older patients, women, minorities, and those living in rural areas are even lower.1 Mendelson et al.2 considered whether patients or their caregivers refusing tPA contributed to these lower rates of tPA use, particularly among black Americans.

How was the study done?

The research team looked back at patients who had acute strokes between January 2013 and June 2015 at 15 Chicago primary stroke centers. These primary stroke centers gave these data to the American Heart Association Get With the Guidelines Stroke registry.3 This registry was started in 2003 to establish best practices for stroke treatment, share information with other member hospitals, and measure their performance.

The patients included in the study came to the emergency department within 4.5 hours from when symptoms began. Some patients were given tPA, while others were not. The research team looked at when patient refusal was listed as the only reason why tPA was not given. They analyzed what factors could have influenced this decision to refuse tPA. These included race–ethnicity, health insurance status, how they arrived (e.g., via ambulance or not), and stroke severity. Patients who had medical reasons for not being given tPA were excluded from the study.

What were the results?

There were 13,662 patients whose records were reviewed for this study. Half of them were women and nearly half (47%) were black. A total of 7.5% of all the patients or their caregivers refused treatment with tPA. More black patients refused (10.6%) compared to patients of other races (4.8%). Those who were older and had prior strokes were also more likely to refuse tPA. Health insurance and stroke severity were also associated with refusing tPA. However, even after controlling for all of these factors, black patients or their caregivers were 2.5 times more likely to refuse tPA.

What does this mean?

This study shows that black patients or their caregivers were more likely to refuse tPA, a medication that can improve how patients recover after a stroke. As neurologists, we would like all patients who can take tPA to receive it and get better. Patients may refuse treatment because they do not know enough about it, because doctors did not fully explain the benefits, or owing to mistrust of doctors in general.

What can be done?

Neurologists can work with community-based organizations to identify cultural and community barriers to receiving tPA. They can develop educational material for different minority groups based on identified community barriers, and continue to invest in public education on acute stroke recognition and its treatments. In addition, there can be increased focus on improving physician communication, particularly among physicians who must explain tPA treatment to patients and get approval. For example, material outlining the benefits and risks of tPA can be provided to physicians so they can inform patients. Physicians could also use visual aids to show these benefits and risks. This is not the only area in neurology where there are racial differences in care.4 These differences should drive neurologists and community partners to address why the differences exist and what can be done about them.

  • © 2018 American Academy of Neurology

References

  1. 1.↵
    1. Messe SR,
    2. Khatri P,
    3. Reeves MJ, et al
    . Why are acute ischemic stroke patients not receiving IV tPA? Neurology 2016;87:1565–1574.
    OpenUrlAbstract/FREE Full Text
  2. 2.↵
    1. Mendelson SJ,
    2. Aggarwal NT,
    3. Richards C,
    4. O'Neill K,
    5. Holl JL,
    6. Prabhakaran S
    . Racial disparities in refusal of stroke thrombolysis in Chicago. Neurology 2018;90:e359–e364.
    OpenUrlAbstract/FREE Full Text
  3. 3.↵
    American Heart Association. High blood pressure guidelines. Available at: heart.org/HEARTORG/HealthcareProfessional/GetWithTheGuidelinesHFStroke/GetWithTheGuidelinesStrokeHomePage/Get-With-The-Guidelines-Stroke-Home-Page_UCM_306098_SubHomePage.jsp. Accessed November 24, 2017.
  4. 4.↵
    1. Saadi A,
    2. Himmelstein DU,
    3. Woolhandler S, et al
    . Racial disparities in neurologic health care access and utilization in the United States. Neurology 2017;88:2268–2275.
    OpenUrlAbstract/FREE Full Text

About stroke and its treatments

What is stroke?

Ischemic stroke, caused by a clot in a blood vessel that cuts off blood flow to the brain, is the most common form of stroke. About 8 out of 10 strokes are ischemic. The other type is called a hemorrhagic stroke (about 2 out of 10 strokes). This is caused by bleeding from a blood vessel into the brain. Symptoms of a stroke include trouble speaking, seeing, or walking, and paralysis or numbness of the face, hands, or legs. FAST is one acronym used to help remember and recognize stroke symptoms. The acronym stands for Facial drooping, Arm weakness, Speech difficulties, and Time. Time is included in the acronym because receiving therapy within a certain time period is crucial. Every minute that therapy is delayed in an ischemic stroke, about 2 million brain cells die. This means that every minute of delay increases the risk of permanent brain damage and disability. Many neurologists say “Time is brain” to emphasize the importance of receiving immediate treatment.

What are the available treatments?

In 1996, the stroke drug tPA was Food and Drug Administration (FDA)–approved for patients with an acute stroke. The drug works by dissolving blood clots. By dissolving the clot, tPA can help to restore blood flow to the brain. The outer time limit of when the drug can be given was initially set at 3 hours from stroke onset, but in 2009 it was extended to 4.5 hours. The sooner someone receives tPA, the better the odds of getting better, so it is important to go to a hospital as soon as stroke symptoms are noticed. Calling 911 immediately and taking an ambulance to the hospital can allow ambulance crews to call ahead to hospitals and alert the stroke team.

It is also important to know that tPA can only be given for an ischemic stroke, and not a hemorrhagic stroke. Giving the clot-busting drug to someone whose stroke is caused by bleeding could be fatal. Hence, before tPA is given, a patient gets a CT scan to make sure there is no bleeding in or around the brain. Other reasons why tPA may not be used include the use of blood thinners like warfarin (Coumadin), recent major surgery, or a history of a prior brain bleed. The major risk with the use of tPA is bleeding, either in the brain or elsewhere in the body.

Another newer FDA-approved therapy for stroke is mechanical thrombectomy. This procedure involves using a device that grabs clots and removes them to re-establish blood flow to the brain. As with tPA, not everyone is a candidate for mechanical thrombectomy. Carefully selecting patients allows doctors to minimize the risks and maximize the benefits of these acute stroke treatments.

The best medicine for stroke is prevention. The use of medications to control high blood pressure and high cholesterol, not smoking, and increasing exercise are the best way to prevent strokes.

For more information

Neurology Now®

http://journals.lww.com/neurologynow/Pages/Resource-Central.aspx

American Stroke Association: A Division of American Heart Association

strokeassociation.org

National Stroke Association

stroke.org

View Abstract

Disputes & Debates: Rapid online correspondence

No comments have been published for this article.
Comment

NOTE: All authors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.

  • Stay timely. Submit only on articles published within the last 8 weeks.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • 200 words maximum.
  • 5 references maximum. Reference 1 must be the article on which you are commenting.
  • 5 authors maximum. Exception: replies can include all original authors of the article.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Disputes & Debates Submission Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
    • Why was the study done?
    • How was the study done?
    • What were the results?
    • What does this mean?
    • What can be done?
    • References
    • What is stroke?
    • What are the available treatments?
    • For more information
  • Info & Disclosures
Advertisement

Related Articles

  • No related articles found.

Topics Discussed

  • All Cerebrovascular disease/Stroke
  • Stroke prevention
  • Other cerebrovascular disease/ Stroke

Alert Me

  • Alert me when this article is cited
  • Alert me if a correction is posted
  • Alert me when eletters are published
Neurology: 93 (24)

Articles

  • Ahead of Print
  • Current Issue
  • Past Issues
  • Popular Articles
  • Translations

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Activate a Subscription
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology | Print ISSN:0028-3878
Online ISSN:1526-632X

© 2019 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise